study of everolimus for autistic spectrum disorder in tuberous sclerosis

study of everolimus for autistic spectrum disorder in tuberous sclerosis - study of everolimus for ASD in TS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024270

Enrollment

Registered

2016-10-03

Start date

2016-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberous sclerosis

Interventions

off-label use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: tuberous sclerosis with ASD symptons tuberous sclerosis with subependymal giant astrocytoma

Exclusion criteria

Exclusion criteria: severe mental retardation

Design outcomes

Primary

Measure	Time frame
scale score for autistic spectrum disorder in 24 weeks	—

Countries

Japan

Contacts

Public ContactTatsuyuki Ohto

University of Tsukuba Pediatrics

tohto@md.tsukuba.ac.jp029-853-3210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026